. "4 The U.S. Military Malaria Vaccine Research and Development Program--Scientific Aspects." Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program. Washington, DC: The National Academies Press, 2006.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Battling Malaria: Strengthening the U.S. Military Malaria Vaccine Program
should aggressively move into clinical trials to test specific vaccineproducts, and select two to three leads at phase 1 and one lead atphase 2 for each strategy. For protein-based and gene-based strategies, the focus should be on specific vaccine products that combinethe lead antigens (CSP, SSP-2/TRAP, LSA-1, AMA-1, and MSP-1)including their use in heterologous prime-boost combinations.
Recommendation 4.4: Finding correlates for protectionin humansrelevant to each of the above vaccine strategies should be a researchpriority.
Recommendation 4.5: The MIDRP Malaria Vaccine Program shouldcontinue research on human immune processes and responses tomalaria. The current incomplete understanding of the mechanismsof protective immunity to malaria in humans constitutes a barrierthat impedes malaria vaccine development.
After thorough review of the MIDRP Malaria Vaccine Program in order to understand the current situation and the program’s quality, the committee concluded that it is crucial to narrow the focus to a smaller number of candidate antigens. Given the limited time available for this review, the committee did not wish to give more detailed specific advice other than that given above and in Recommendation 4.3. Despite having extensive expertise in all scientific aspects of the program, the committee concluded that instead of offering one-time advice on specific antigens or approaches, it would be more productive to recommend a structure and process for ongoing review and decision making about the scientific direction of the work.